The emergence of nanoparticle-mediated drug delivery has transformed the landscape of cancer therapy, offering unprecedented specificity, reduced systemic toxicity, and enhanced therapeutic efficacy. The complexity of the tumor microenvironment, coupled with heterogeneous cancer cell populations and immune escape mechanisms, necessitates multifaceted approaches that integrate nanotechnology, immunotherapy, and precision medicine. This review explores the theoretical foundations, experimental methodologies, and translational implications of nanoparticle-based interventions in oncology, with a particular focus on breast cancer and hematologic malignancies. We critically examine the role of polymeric, lipid-based, and hybrid Nano carriers in achieving active targeting, controlled drug release, and synergistic combination therapy. Furthermore, challenges associated with nanoparticle penetration, bio distribution, and clearance are addressed, highlighting recent innovations in surface functionalization, stimuli-responsive designs, and biocompatible formulations. Detailed analysis of preclinical and clinical studies reveals that co-delivery strategies—such as the concurrent administration of chemotherapeutics with immunomodulatory agents—demonstrate superior outcomes in overcoming drug resistance and inducing apoptosis in refractory tumor cells. Limitations regarding heterogeneity in patient responses, off-target effects, and translational scalability are discussed, alongside recommendations for the integration of computational modeling, high-throughput screening, and genotype-informed treatment planning. Finally, future perspectives emphasize the convergence of Nano medicine with systems biology, personalized immunotherapy, and artificial intelligence-driven predictive modeling to achieve precision oncology. This comprehensive synthesis underscores the potential of nanoparticle-mediated approaches to redefine cancer treatment paradigms while recognizing the nuanced complexities that must be addressed for widespread clinical implementation.

Nanoparticles, Targeted drug delivery, Breast cancer, Tumor microenvironment, , Combination therapy, Immunotherapy, Polymeric Nano carriers

Baghban R., Roshangar L., Jahanban-Esfahlan R., Seidi K., Ebrahimi-Kalan A., Jaymand M., et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 18 (1), 59. 10.1186/s12964-020-0530-4

Bai C., Hu P., Zhang W., Song L., Liu D., Chen Y., et al. Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy. Nanoscale 12 (35), 18418–18428. 10.1039/D0NR04450D

Barnett G. C., West C. M., Dunning A. M., Elliott R. M., Coles C. E., Pharoah P. D., et al. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. Nat. Rev. Cancer 9 (2), 134–142. 10.1038/nrc2587

Barua S., Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. Nano Today 9 (2), 223–243. 10.1016/j.nantod.2014.04.008

Baskar R., Lee K. A., Yeo R., Yeoh K. W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 9 (3), 193–199. 10.7150/ijms.3635

Bauer T. A., Horvat N. K., Marques O., Chocarro S., Mertens C., Colucci S., et al. Core cross-linked polymeric micelles for specific iron delivery: Inducing sterile inflammation in macrophages. Adv. Healthc. Mat. 10 (19), e2100385. 10.1002/adhm.202100385

Bayat Mokhtari R., Homayouni T. S., Baluch N., Morgatskaya E., Kumar S., Das B., et al. Combination therapy in combating cancer. Oncotarget 8 (23), 38022–38043. 10.18632/oncotarget.16723

Bayda S., Adeel M., Tuccinardi T., Cordani M., Rizzolio F. The history of nanoscience and nanotechnology: From chemical-physical applications to nanomedicine. Molecules 25 (1), 112. 10.3390/molecules25010112

Bazak R., Houri M., El Achy S., Kamel S., Refaat T. Cancer active targeting by nanoparticles: A comprehensive review of literature. J. Cancer Res. Clin. Oncol. 141 (5), 769–784. 10.1007/s00432-014-1767-3

Beatty G. L., Gladney W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21 (4), 687–692. 10.1158/1078-0432.Ccr-14-1860

Verma R., Singh V., Koch B., Kumar M. Evaluation of methotrexate encapsulated polymeric nanocarrier for breast cancer treatment. Colloids Surfaces B Biointerfaces, 226, Article 113308. 10.1016/J.COLSURFB.2023.113308

Kitsios K., Sharifi S., Mahmoudi M. Nanomedicine technologies for diagnosis and treatment of breast cancer. ACS Pharmacol. Transl. Sci., 6 (5), 671-682. 10.1021/ACSPTSCI.3C00044

Valcourt D. M., Dang M. N., Scully M. A., Day E. S. Nanoparticle-mediated Co-delivery of notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer. ACS Nano, 14 (3), 3378-3388. 10.1021/ACSNANO.9B09263

Iqbal H., et al. pH-responsive albumin-coated biopolymeric nanoparticles with lapatinib for targeted breast cancer therapy. Biomater. Adv., 139, Article 213039. 10.1016/J.BIOADV.2022.213039

Pourgholi A., Dadashpour M., Mousapour A., Amandi A. F., Zarghami N. Anticancer potential of silibinin loaded polymeric nanoparticles against breast cancer cells: insight into the apoptotic genes targets. Asian Pac. J. Cancer Prev., 22 (8), 2587. 10.31557/APJCP.2021.22.8.2587

Koual M., et al. Associations between persistent organic pollutants and risk of breast cancer metastasis. Environ. Int., 132, Article 105028. 10.1016/J.ENVINT.2019.105028

Jafari-Gharabaghlou D., Dadashpour M., Khanghah O. J., Salmani-Javan E., Zarghami N. Potentiation of Folate